The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D
研究利用Medicare D部分数据，发现2019-2023年间非糖尿病患者使用GLP-1药物的比例从9.0%升至13.8%，且多见于年轻女性肥胖者，对医保预算有重大影响。
OBJECTIVE: To assess the extent of off-label glucagon-like peptide-1 receptor agonist (GLP-1) prescribing among individuals without diabetes in Medicare Part D. STUDY SETTING AND DESIGN: This cross-sectional study included Medicare Part D beneficiaries who initiated GLP-1s. We used a difference-in-differences event-study design with insulin initiators as a control group to interpret time trends in prescribing without diabetes evidence. DATA SOURCES AND ANALYTIC SAMPLE: We identified beneficiaries initiating semaglutide or tirzepatide between 2019 and 2023 using a 20% sample of Part D event data. Nondiabetic use was defined as the absence of a diabetes diagnosis or a prescription history of diabetes medications within 1 year before or after 6 months of the first GLP-1 fill. PRINCIPAL FINDINGS: Among 126,263 new GLP-1 users, 9.0% were prescribed without diabetes, rising to 13.8% in 2023. This practice was more common among younger, female beneficiaries with obesity. From 2021 to 2023, the share of initiators without diabetes evidence increased by 13.3 percentage points (95% CI, 12.9-13.6), beyond changes observed among insulin initiators. CONCLUSIONS: This growth underscores the substantial budgetary implications for Medicare, particularly amid ongoing policy discussions around expanding coverage of GLP-1s for weight management.